A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).
1 other identifier
interventional
3,800
8 countries
154
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2004
154 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2004
CompletedFirst Submitted
Initial submission to the registry
August 26, 2005
CompletedFirst Posted
Study publicly available on registry
August 30, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2006
CompletedFebruary 17, 2012
February 1, 2012
2.1 years
August 26, 2005
February 15, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
LDL and HDL levels
Secondary Outcomes (1)
other lipid parameters
Interventions
Eligibility Criteria
You may qualify if:
- subjects with elevated cholesterol
You may not qualify if:
- Women who are pregnant or lactating, or planning to become pregnant.
- Intolerance to statin therapy resulting in withdrawal
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (154)
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Oro Valley, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Sun City, Arizona, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Concord, California, United States
Pfizer Investigational Site
Greenbrae, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Mission Viejo, California, United States
Pfizer Investigational Site
Sacramento, California, United States
Pfizer Investigational Site
Santa Ana, California, United States
Pfizer Investigational Site
Stockton, California, United States
Pfizer Investigational Site
Thouasand Oaks, California, United States
Pfizer Investigational Site
Tustin, California, United States
Pfizer Investigational Site
Upland, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Westlake Village, California, United States
Pfizer Investigational Site
Boulder, Colorado, United States
Pfizer Investigational Site
Waterbury, Connecticut, United States
Pfizer Investigational Site
Newark, Delaware, United States
Pfizer Investigational Site
Coral Gables, Florida, United States
Pfizer Investigational Site
Ft. Pierce, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jupiter, Florida, United States
Pfizer Investigational Site
Lake Worth, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Palm Bay, Florida, United States
Pfizer Investigational Site
Sebastian, Florida, United States
Pfizer Investigational Site
Stuart, Florida, United States
Pfizer Investigational Site
Vero Beach, Florida, United States
Pfizer Investigational Site
Wellington, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Creve Coevr, Illinois, United States
Pfizer Investigational Site
Peoria, Illinois, United States
Pfizer Investigational Site
Rockford, Illinois, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Kansas City, Kansas, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Erlanger, Kentucky, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
Slidell, Louisiana, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Bethesda, Maryland, United States
Pfizer Investigational Site
Elkton, Maryland, United States
Pfizer Investigational Site
Jackson, Mississippi, United States
Pfizer Investigational Site
Jefferson City, Missouri, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Billings, Montana, United States
Pfizer Investigational Site
Lincoln, Nebraska, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Endwell, New York, United States
Pfizer Investigational Site
Lake Success, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Concord, North Carolina, United States
Pfizer Investigational Site
Fayetteville, North Carolina, United States
Pfizer Investigational Site
Monroe, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Elyria, Ohio, United States
Pfizer Investigational Site
Olmsted, Ohio, United States
Pfizer Investigational Site
Westlake, Ohio, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Beaverton, Oregon, United States
Pfizer Investigational Site
Hillsboro, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Warwick, Rhode Island, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Spartanburg, South Carolina, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Bryan, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
The Colony, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Newport News, Virginia, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Renton, Washington, United States
Pfizer Investigational Site
Yakima, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Oregon, Wisconsin, United States
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Dottignies, Belgium
Pfizer Investigational Site
Ham, Belgium
Pfizer Investigational Site
Hasselt, Belgium
Pfizer Investigational Site
Hoeilaart, Belgium
Pfizer Investigational Site
La Louvière, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Wilsele, Belgium
Pfizer Investigational Site
Beckum, Germany
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Bochum, Germany
Pfizer Investigational Site
Erlangen, Germany
Pfizer Investigational Site
Essen, Germany
Pfizer Investigational Site
Feldafing, Germany
Pfizer Investigational Site
Hamburg, Germany
Pfizer Investigational Site
Heidelberg, Germany
Pfizer Investigational Site
Homburg/Saar, Germany
Pfizer Investigational Site
Karlsruhe, Germany
Pfizer Investigational Site
Künzing, Germany
Pfizer Investigational Site
Nuremberg, Germany
Pfizer Investigational Site
Offenbach, Germany
Pfizer Investigational Site
Rodgau, Germany
Pfizer Investigational Site
Schwerin, Germany
Pfizer Investigational Site
México, D.f., Mexico
Pfizer Investigational Site
Tlalpan, D.f., Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Puebla City, Puebla, Mexico
Pfizer Investigational Site
Bekkestua, Norway
Pfizer Investigational Site
Elverum, Norway
Pfizer Investigational Site
Hønefoss, Norway
Pfizer Investigational Site
Jessheim, Norway
Pfizer Investigational Site
Kongsberg, Norway
Pfizer Investigational Site
Lena, Norway
Pfizer Investigational Site
Lierskogen, Norway
Pfizer Investigational Site
Molde, Norway
Pfizer Investigational Site
Moss, Norway
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
Roverud, Norway
Pfizer Investigational Site
Skedsmokorset, Norway
Pfizer Investigational Site
Tromsø, Norway
Pfizer Investigational Site
Seoul, South Korea
Pfizer Investigational Site
Suwon, South Korea
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Jarfalla, Sweden
Pfizer Investigational Site
Linköping, Sweden
Pfizer Investigational Site
Örebro, Sweden
Pfizer Investigational Site
Strängnäs, Sweden
Pfizer Investigational Site
Umeå, Sweden
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Woolwell, Plymouth, Devon, United Kingdom
Pfizer Investigational Site
Middlesex, Harrow, United Kingdom
Pfizer Investigational Site
Garston, Hertfordshire, United Kingdom
Pfizer Investigational Site
Blackpool, Lancashire, United Kingdom
Pfizer Investigational Site
Blackpool, Lancs. Fy3 7dq, United Kingdom
Pfizer Investigational Site
Addlestone, Surrey, United Kingdom
Pfizer Investigational Site
East Horsley, Leatherhead, Surrey, United Kingdom
Pfizer Investigational Site
Warminster, Wiltshire, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 26, 2005
First Posted
August 30, 2005
Study Start
July 1, 2004
Primary Completion
August 1, 2006
Study Completion
August 1, 2006
Last Updated
February 17, 2012
Record last verified: 2012-02